Immuneering (IMRX) Payables (2020 - 2026)

Immuneering's Payables history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Payables rose 10.88% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 10.88% YoY), while the FY2025 annual figure was $1.5 million, down 21.23% from the prior year.
• Payables was $1.5 million for Q1 2026 at Immuneering, down from $1.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $3.2 million in Q4 2022 to a low of $1.2 million in Q2 2022.
• Historically, Payables has averaged $2.1 million across 5 years, with a median of $2.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Payables soared 126.24% in 2022, then plunged 42.29% in 2025.
• A 5-year view of Payables shows it stood at $3.2 million in 2022, then sank by 33.06% to $2.1 million in 2023, then dropped by 7.25% to $2.0 million in 2024, then decreased by 21.23% to $1.5 million in 2025, then slipped by 5.81% to $1.5 million in 2026.
• The last three Payables figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.